Pharmacokinetic Characterization of Three Doses of Tipranavir Boosted with Ritonavir on Highly Active Antiretroviral Therapy in Treatment-Experienced HIV-1 Patients

被引:2
作者
Goebel, Frank D. [2 ]
MacGregor, Thomas R. [1 ]
Sabo, John P. [1 ]
Castles, Mark [1 ]
Johnson, Philip A. [1 ]
Legg, Daniel [1 ]
McCallister, Scott
机构
[1] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT 06877 USA
[2] Univ Munich, Med Poliklin, D-8000 Munich, Germany
来源
HIV CLINICAL TRIALS | 2010年 / 11卷 / 01期
关键词
antiretrovirals; drug-drug interactions; ritonavir; tipranavir; NONPEPTIDIC PROTEASE INHIBITOR; INFECTED PATIENTS; HIV-1-INFECTED PATIENTS; 1-INFECTED PATIENTS; HEALTHY-VOLUNTEERS; DRUG-INTERACTIONS; EFFICACY; METABOLISM; ZIDOVUDINE; SAFETY;
D O I
10.1310/hct1101-28
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
This study characterized the pharmacokinetic effects, safety, and antiretroviral activity of three different doses of the nonpeptidic protease inhibitor tipranavir, in combination with ritonavir administered twice daily for 28 days, on a number of triple-combination regimens containing a nonnucleoside reverse transcriptase inhibitor (efavirenz or nevirapine) plus two nucleoside reverse transcriptase inhibitors (abacavir, didanosine, lamivudine, stavudine, and zidovudine) or a three nucleoside reverse transcriptase inhibitor combination (zidovudine, lamivudine, and abacavir). Methods: The study enrolled 208 HIV-1 positive patients who had been on stable antiretroviral treatment for at least 12 weeks prior to study entry and had an HIV-1 RNA load of <= 20,000 copies/mL. The patients were randomized to receive one of three dose combinations of tipranavir and ritonavir (1250/100 mg, 750/100 mg, and 250/200 mg) in addition to their antiretroviral (ARV) regimen for the next 22 days. The effects of twice-daily tipranavir and ritonavir combinations on the steady-state pharmacokinetics of the antiretrovirals were assessed by comparing pharmacokinetic parameters at baseline and after 3 weeks of coadministration. Results: No clinically relevant changes were observed in the C-min, C-max, or AUC parameters for nevirapine, efavirenz, lamivudine, stavudine, or didanosine, when coadministered with tipranavir and ritonavir at the dose combinations studied. All three dose combinations of tipranavir and ritonavir decreased the systemic exposure of abacavir (by 35% to 44%) and zidovudine (by 31% to 42%). Consistent with previous tipranavir studies, gastrointestinal adverse events were those most frequently observed. These reactions tended to be mild, with the majority being of Grade 1, and only 8 being of Grade 3 or 4 in intensity. Virologic response improved from 40.4% of participants at baseline with <50 copies/mL to 67.6% at Day 28 of study following addition of tipranavir and ritonavir. Conclusions: Tipranavir coadministered with ritonavir has been demonstrated to be safe, effective, and pose little potential for clinically meaningful drug interactions when added to the highly active antiretroviral therapy regimens containing nevirapine, efavirenz, lamivudine, stavudine, or didanosine.
引用
收藏
页码:28 / 38
页数:11
相关论文
共 29 条
[11]   Efficacy of the protease inhibitors tipranavir plus ritonavir in treatment-experienced patients: 24-week analysis from the RESIST-1 trial [J].
Gathe, Joseph ;
Cooper, David A. ;
Farthing, Charles ;
Jayaweera, Dushyantha ;
Norris, Dorece ;
Pierone, Gerald, Jr. ;
Steinhart, Corklin R. ;
Trottier, Benoit ;
Walmsley, Sharon L. ;
Workman, Cassy ;
Mukwaya, Geoffrey ;
Kohlbrenner, Veronika ;
Dohnanyi, Catherine ;
McCallister, Scott ;
Mayers, Douglas .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (10) :1337-1346
[12]   Efficacy and safety of three doses of tipranavir boosted with ritonavir in treatment-experienced HIV type 1-infected patients [J].
Gathe, Joseph C., Jr. ;
Pierone, Gerald ;
Piliero, Peter ;
Arasteh, Keikawus ;
Rubio, Rafael ;
Lalonde, Richard G. ;
Cooper, David ;
Lazzarin, Adriano ;
Kohlbrenner, Veronika M. ;
Dohnanyi, Catherine ;
Sabo, John ;
Mayers, Douglas .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (02) :216-223
[13]   Antiretroviral treatment of adult HIV infection - 2008 recommendations of the International AIDS Society USA panel [J].
Hammer, Scott M. ;
Eron, Joseph J., Jr. ;
Reiss, Peter ;
Schooley, Robert T. ;
Thompson, Melanie A. ;
Walmsley, Sharon ;
Cahn, Pedro ;
Fischl, Margaret A. ;
Gatell, Jose M. ;
Hirsch, Martin S. ;
Jacobsen, Donna M. ;
Montaner, Julio S. G. ;
Richman, Douglas D. ;
Yeni, Patrick G. ;
Volberding, Paul A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 300 (05) :555-570
[14]   Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials [J].
Hicks, Charles B. ;
Cahn, Pedro ;
Cooper, David A. ;
Walmsley, Sharon L. ;
Katlama, Christine ;
Clotet, Bonaventura ;
Lazzarin, Adriano ;
Johnson, Margaret A. ;
Neubacher, Dietmar ;
Mayers, Douglas ;
Valdez, Hernan .
LANCET, 2006, 368 (9534) :466-475
[15]   Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005 [J].
Hoen, Bruno ;
Cooper, David A. ;
Lampe, Fiona C. ;
Perrin, Luc ;
Clumeck, Nathan ;
Phillips, Andrew N. ;
Goh, Li-Ean ;
Lindback, Stefan ;
Sereni, Daniel ;
Gazzard, Brian ;
Montaner, Julio ;
Stellbrink, Hans-Jurgen ;
Lazzarin, Adriano ;
Ponscarme, Diane ;
Staszewski, Shlomo ;
Mathiesen, Lars ;
Smith, Don ;
Finlayson, Robert ;
Weber, Rainer ;
Wegmann, Laurence ;
Janossy, George ;
Kinloch-de Loes, Sabine .
CLINICAL INFECTIOUS DISEASES, 2007, 45 (03) :381-390
[16]   Pharmacokinetic interaction between mefloquine and ritonavir in healthy volunteers [J].
Khaliq, Y ;
Gallicano, K ;
Tisdale, C ;
Carignan, G ;
Cooper, C ;
McCarthy, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (06) :591-600
[17]  
Koudriakova T, 1998, DRUG METAB DISPOS, V26, P552
[18]  
Kumar GN, 1999, DRUG METAB DISPOS, V27, P902
[19]   Tipranavir inhibits broadly protease inhibitor-resistant HIV-1 clinical samples [J].
Larder, BA ;
Hertogs, K ;
Bloor, S ;
van den Eynde, C ;
DeCian, W ;
Wang, YY ;
Freimuth, WW ;
Tarpley, G .
AIDS, 2000, 14 (13) :1943-1948
[20]   Pharmacokinetic characterization of different dose combinations of coadministered tipranavir and ritonavir in healthy volunteers [J].
MacGregor, TR ;
Sabo, JP ;
Norris, SH ;
Johnson, P ;
Galitz, L ;
McCallister, S .
HIV CLINICAL TRIALS, 2004, 5 (06) :371-382